About Us
The vision for Jade Capital Advisors was to create a corporate finance advisory firm that would capitalize on a broader set of experiences.
The Jade Capital Advisors senior team not only brings transactional expertise from our capital markets, investment banking/M&A and private equity backgrounds, but also strong industry knowledge from serving on various corporate boards of Directors and consulting, all of which makes Jade Capital Advisors capable of delivering the best possible solutions to our clients. This diversity of backgrounds gives us multiple inroads into companies allowing us to analyze situations from varying perspectives.
Jade Capital Advisors is an international financial advisory firm operating in Asia, Europe and the Americas with presence in the United States, Belgium, Singapore, and mainland China.
Jade Capital Advisors is represented by ambitious and dedicated professionals with extensive experience and deep-rooted networks in a variety of sectors internationally. We are service-driven and passionately-dedicated solely to the success of our clients. If you are looking for strategic partner with a proven track record – do not hesitate to contact us. We look forward to serving you.
Strategic Advisory
Senior members of Jade Capital Advisors have extensive experience in mergers & acquisitions, debt and equity capital origination and distressed asset refinancing all of which we have worked on both the buy and sell sides, completing more than 100 transactions in aggregate. We also have successfully assisted our clients with strategic business plan development and corporate restructurings.
Our clients have included large publicly-traded clients and privately-held middle-market companies based in the U.S., Europe and Asia, across multiple industries including Consumer Product Manufacturing, Education Technology, Financial Services (Private Equity), Financial Technology, and the Pharmaceutical and Biotechnology sectors.
Transaction advisory to Life Sciences clients in North America, Europe and Asia including the Pharmaceutical, Biotech and Medical Technology industries. Our profile of transactions include debt and equity capital issuance, in/out-licensing, acquisitions and corporate restructurings.
